Log in
Enquire now
‌

US Patent RE42014 Pharmaceutical compositions

Patent RE42014 was granted and assigned to Novartis on December, 2010 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Patent abstractTimelineTable: Further ResourcesReferences
Is a
Patent
Patent

Patent attributes

Current Assignee
Novartis
Novartis
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
RE42014
Patent Inventor Names
Harry Tiemessen1
Date of Patent
December 28, 2010
Patent Application Number
10345665
Date Filed
January 20, 1997
Patent Primary Examiner
‌
James D. Anderson
Patent abstract

A process for preparing an emulsion composition comprising a cyclosporin, a rapamycin or an ascomycin or a derivative thereof as active agent, which process comprises the step of admixing to a placebo fat emulsion a concentrate comprisinga) the active agent,b) a stabiliser selected from a phospholipid, a glycolipid, a sphingolipid, a diacylphosphatidyl glycerol, an egg-phosphatidylglycerol, a soy-phosphatidylglycerol, a diacylphosphatidylglycerol, or a salt thereof; or a saturated, mono- or di-unsaturated (C12-24) fatty acid, or a salt thereof, andc) an organic solvent,wherein the weight ratio of active agent to stabiliser is between 400:1 and 0.5:1.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent RE42014 Pharmaceutical compositions

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.